Stories
Drug Control Committee Rejects Public Disclosure of Medicine Quality Reports.
N
News18•02-10-2026, 20:21
Drug Control Committee Rejects Public Disclosure of Medicine Quality Reports.
- •The Drugs Consultative Committee (DCC) has rejected a proposal to make quality testing reports of medicine batches available on a public digital platform.
- •The proposal aimed to mandate pharmaceutical manufacturers to upload the test report or Certificate of Analysis (CoA) of every batch of their medicines publicly.
- •The objective was to enhance transparency regarding medicine quality, allowing consumers and healthcare professionals to view test results.
- •This decision was recorded in the minutes of the 70th meeting of the DCC, held on September 18.
- •The DCC is a regulatory advisory body comprising drug regulators from the Center and States, playing a key role in drug regulatory coordination.
Key Questions Answered
The Drugs Consultative Committee (DCC) rejected a proposal to require pharmaceutical manufacturers to upload the batch test reports or Certificates of Analysis (CoA) of their medicines onto a public digital platform for consumers to view.
A Certificate of Analysis (CoA) is a document prepared by a pharmaceutical company after checking the quality of a medicine batch, detailing whether the batch passed prescribed quality tests and outlining its specific test results.
The primary goal of the proposal was to enhance transparency regarding medicine quality by allowing consumers, healthcare professionals, and others to view the quality testing results of specific medicine batches.
